Why the study?
Does N-acetylprocainamide reduce the incidence of systemic lupus erythematosus compared to procainamide in patients treated for cardiac arrhythmias?
Population
Patients receiving long-term therapy for cardiac arrhythmias
Comparison
N-acetylprocainamide (NAPA) vs Procainamide (PA)
Design
Review
Follow-up
Long-term
Authors
Loading...
Supports NAPA preference to minimize SLE risk versus procainamide; hypothesis-generating without randomized confirmation in arrhythmia patients.
Does N-acetylprocainamide reduce the incidence of systemic lupus erythematosus compared to procainamide in patients treated for cardiac arrhythmias?
N-acetylprocainamide is a safer alternative to procainamide for cardiac arrhythmias, as it retains antiarrhythmic efficacy without the high risk of inducing systemic lupus erythematosus.
Reidenberg et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: